Skip to main content
Top
Published in: Drug Safety 10/2010

01-10-2010 | Editorial

Reflections on Attribution and Decisions in Pharmacovigilance

Authors: Ola Caster, I. Ralph Edwards

Published in: Drug Safety | Issue 10/2010

Login to get access

Excerpt

In general, a causal relationship depends upon the nature and amount of evidence supporting an attribution hypothesis, such that ‘A causes B’. A can be a sufficient cause of B, meaning that A is always followed by B; or a necessary cause, meaning that B cannot occur without being preceded by A; or both. These deterministic concepts are not relevant to pharmacovigilance. No drug is a sufficient cause of an adverse effect, and there are no examples of necessary causes either. The trigger to modern pharmacovigilance, thalidomide, has come close to being considered a necessary cause of phocomelia, but this is not true. Phocomelia is very rare in the absence of thalidomide but not vanishingly so; x-irradiation is one example of another cause.[1] This example is illuminating also because it shows that the definition of the hypothesis is critical: one must be sure one knows what A and B are. In this case we have used the terms phocomelia, ectromelia, amelia and limb-reduction disorder loosely as synonyms when in reality they are overlapping hierarchical entities. …
Literature
1.
go back to reference Galloway JL, Delgado I, Ros MA, et al. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature 2009; 460(7253): 400–4PubMed Galloway JL, Delgado I, Ros MA, et al. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature 2009; 460(7253): 400–4PubMed
2.
go back to reference Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006 Dec; 333(7581): 1267–9PubMedCrossRef Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006 Dec; 333(7581): 1267–9PubMedCrossRef
3.
go back to reference Hill AB. The environment and disease: association or casuation? Proc R Soc Med 1965; 58(5): 295–300PubMed Hill AB. The environment and disease: association or casuation? Proc R Soc Med 1965; 58(5): 295–300PubMed
4.
go back to reference Hauben M, Aronson JK. Defining ‘signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110PubMedCrossRef Hauben M, Aronson JK. Defining ‘signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110PubMedCrossRef
6.
go back to reference Edwards IR, Lindquist M, Wiholm BE, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990 Jul; 336(8708): 156–8PubMedCrossRef Edwards IR, Lindquist M, Wiholm BE, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990 Jul; 336(8708): 156–8PubMedCrossRef
7.
go back to reference Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367–73PubMedCrossRef Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367–73PubMedCrossRef
8.
go back to reference Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan–Feb; 12(1): 17–29PubMedCrossRef Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan–Feb; 12(1): 17–29PubMedCrossRef
9.
go back to reference Bowdler J, editor. Effective communications in pharmacovigilance: the Erice report. Uppsala: The Uppsala Monitoring Centre, 1998 Bowdler J, editor. Effective communications in pharmacovigilance: the Erice report. Uppsala: The Uppsala Monitoring Centre, 1998
Metadata
Title
Reflections on Attribution and Decisions in Pharmacovigilance
Authors
Ola Caster
I. Ralph Edwards
Publication date
01-10-2010
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2010
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11532460-000000000-00000

Other articles of this Issue 10/2010

Drug Safety 10/2010 Go to the issue